New Elite Feature: Screen & Chart at the same time

Oncolytics Biotech, Inc.

Contributing Author

Recent Articles by Oncolytics Biotech, Inc.

May-04	Oncolytics Biotech Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer ONCY +6.61% GlobeNewswire
Apr-27	Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study ONCY -5.95% GlobeNewswire
Apr-06	Oncolytics Biotech Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer ONCY GlobeNewswire
Apr-01	Oncolytics Biotech Completes Domicile Change to the United States ONCY +9.58% GlobeNewswire
Mar-19	Oncolytics Biotech to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 ONCY GlobeNewswire
Mar-02	Oncolytics Biotech Launches Randomized Colorectal Cancer Study ONCY -9.73% GlobeNewswire
Feb-24	Oncolytics Biotech to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer ONCY +6.60% GlobeNewswire
Feb-04	Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer ONCY GlobeNewswire
Jan-15	Oncolytics Biotech Announces Results of Special Meeting of Shareholders ONCY -7.33% GlobeNewswire
Jan-14	Oncolytics Biotech Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics ONCY GlobeNewswire
Jan-12	Oncolytics Biotech Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer ONCY GlobeNewswire
Jan-09	Oncolytics Biotech Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada ONCY GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)